Inclusion Criteria:

- Histologically/cytologically documented SCCHN, excluding nasopharyngeal carcinoma.
Squamous cell carcinomas of unknown primary are allowed. Primary salivary gland
tumors and tumor of the nasal cavity and paranasal sinuses are not included.

- 18 years of age or older.

- Evaluable or uni-dimensionally measurable local-regional and/or metastatic disease
that is not amendable to primary surgical resection or radiotherapy.

- Life expectancy of at least 3 months.

- ECOG performance status of 0-2.

- Negative pregnancy test for women of childbearing potential.

- Adequate bone marrow function.

Exclusion Criteria:

- Evidence of sever or uncontrolled systemic disease or any concurrent condition which
in the investigator's opinion makes it undesirable for the patient to participate in
the trial.

- Clinically significant cardiac event such as myocardial infarction, NYHA
classification of heart disease grade II or higher within 3 months of study entry, or
presence of cardiac disease that, in the opinion of the investigator, increases the
risk of ventricular arrhythmia.

- History of arrhythmia which is symptomatic or requires treatment or asymptomatic
sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is
not excluded.

- Previous history of QTc prolongation as a result from other medication that required
discontinuation of that medication.

- Congenital long QT syndrome, or 1st degree relative with unexplained sudden death
under 40 years of age.

- Presence of left bundle branch block.

- QTc with Bazett's correction that is unmeasurable or > 480 msec on screening ECG.

- Any concomitant medication that may cause QTC prolongation, induce Torsades de
Pointes or induce CYP3A4 function.

- Hypertension not controlled by medical therapy.

- Currently active diarrhea that may affect the ability of the patient to absorb
Zactima.

- Pregnant or breast-feeding women.

- Previous or concurrent malignancies of other histologies within the last 5 years,
with the exception of cervical carcinoma in-situ and adequately treated basal cell or
squamous cell carcinoma of the skin.

- Receipt of any investigational agents within 30 days prior to commencing study
treatment.

- Prior treatment with docetaxel.

- Last dose of prior chemotherapy discontinued less than 3 weeks before start of study
therapy.

- Last dose of radiation therapy within the last 4 weeks before the start of study
therapy, except palliative radiotherapy.

- Major surgery within 4 weeks, or incompletely healed surgical incision.